Paclitaxel, sold under the brand name Taxol, was first isolated from the bark of the Pacific yew tree (Taxus brevifolia) in the late 1960s and has since become one of the most widely used cancer drugs in the world. It is approved for treatment of ovarian, breast, and lung cancer, and used against numerous other tumor types. But the path from a slow-growing understory tree in the Pacific Northwest to a modern chemotherapy staple involved ecological crisis, intellectual property battles, and decades of creative chemistry to free the drug from its scarce natural source.
How Taxol Was Found
The discovery traces back to a large-scale effort by the U.S. National Cancer Institute (NCI) in the 1960s, which collected thousands of plant samples looking for compounds that could fight tumors. Bark from Taxus brevifolia, collected in Washington State, showed activity against cancer cells in lab tests. In 1971, Monroe Wall and Mansukh Wani published the isolation and chemical structure of the active compound, which they named taxol.1ACS Publications. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia The compound’s complex molecular architecture was unlike anything chemists had seen, and its development into a usable drug would take another two decades of painstaking work.
How Paclitaxel Kills Cancer Cells
Most cells rely on an internal scaffolding system made of tiny protein tubes called microtubules. These structures are constantly assembling and disassembling, and they play a critical role during cell division by pulling chromosomes apart. Paclitaxel locks microtubules into their assembled state, preventing them from breaking down when they need to.2PubMed Central. Cellular Interactome Dynamics during Paclitaxel Treatment That stabilization comes with a physical change in the microtubule’s structure at the molecular level.3PubMed. How does taxol stabilize microtubules?
The result is that dividing cancer cells get stuck. They enter mitosis but cannot complete it, which triggers cell death. Interestingly, the drug’s effects depend heavily on concentration. At higher doses, cells arrest cleanly in mitosis. But at the lower concentrations that actually reach tumors in living patients, the outcome is messier: cells undergo abnormal, multipolar divisions rather than a tidy arrest, and this still leads to their destruction.4Europe PMC / Molecular Biology of the Cell. How Taxol/paclitaxel kills cancer cells Research in lung cancer cells has shown that even extremely low concentrations of paclitaxel can trigger programmed cell death, and that this effect kicks in before full mitotic arrest is even detectable.5PubMed. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition
Beyond straightforward programmed cell death, paclitaxel also pushes cells into other destructive fates. Work on gastric cancer cells found that the drug triggers a cascade: cells first undergo what is called mitotic catastrophe, becoming abnormally large with multiple nuclei. Those multinucleated cells then lose the proteins they need to keep dividing and essentially become senescent, a state where they are alive but permanently unable to grow.6Scientific Reports. The effect of paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells So the drug does not just kill cells through one pathway; it pushes them toward death through several overlapping mechanisms.
The Ecological Problem With Bark Harvesting
Pacific yew is a slow-growing tree that lives in the shade of larger conifers across the mountains of western Oregon and Washington. It is classified as a late-successional species, meaning it reaches its highest density in old-growth forests and is slow to recover after disturbance.7PubMed. Ecology of Pacific Yew (Taxus brevifolia) in Western Oregon and Washington It is sensitive to fire and colonizes new habitat slowly, which means that once a population is disrupted, it can take decades or longer to bounce back.
This ecology made the tree a poor candidate for industrial-scale bark harvesting. Producing enough paclitaxel to treat a single patient required stripping the bark from multiple mature trees, killing them in the process. As clinical trials demonstrated the drug’s effectiveness in the late 1980s and early 1990s, demand surged, and large numbers of Pacific yew were felled for their bark.8Semantic Scholar. Stump sprouting of Pacific yew Conservation biologists and environmentalists raised alarms about the sustainability of this approach, and the situation created an unusually sharp tension between a life-saving medicine and a vulnerable forest species.
Some hope for recovery lay in the tree’s ability to sprout from stumps after being cut. Research found that sprouting was most successful on stumps that already had established sprouts or live branches before harvesting.8Semantic Scholar. Stump sprouting of Pacific yew Interest also grew in cultivating the species, though its shade-tolerant nature raised questions about whether it could handle the bright conditions of a nursery or open regeneration site.9Tree Physiology. Acclimation of Pacific yew (Taxus brevifolia) foliage to sun and shade Fortunately, the supply problem was ultimately resolved not by growing more yew trees but by finding alternatives to bark altogether.
How Chemists Freed Paclitaxel From the Tree
The supply crisis pushed researchers in several directions at once. The most elegant solution came from semisynthesis: starting with a related compound found in the needles of the European yew (Taxus baccata) and converting it into paclitaxel in the lab. Unlike bark harvesting, collecting needles does not kill the tree. Researchers showed that a precursor compound could be extracted from fresh needles and then converted to paclitaxel in four chemical steps with a strong overall yield.10Journal of the Serbian Chemical Society. Semisynthesis of Taxol: An improved procedure for the isolation of 10-deacetylbaccatin III This approach became the backbone of commercial paclitaxel production and largely ended the pressure on wild Pacific yew populations.
Meanwhile, organic chemists took on one of the great challenges in their field: the total synthesis of taxol from simple starting materials. Robert Holton’s group achieved this in 1994, publishing a convergent synthetic strategy that could produce both the natural compound and designed variants.11PubMed. Total synthesis of taxol The synthesis was a landmark in chemistry, recognized alongside other famously complex molecules.12PubMed Central. Inspirations, discoveries, and future perspectives in total synthesis Total synthesis remains too expensive and low-yielding for mass production, but it proved the concept and opened the door to creating modified versions of paclitaxel that nature never made.
A third approach uses plant cell culture: growing yew cells in bioreactors rather than in forests. This has matured into a commercially viable method. The German company Phyton Biotech produces FDA-approved paclitaxel using this technology, and a South Korean company has developed a paclitaxel product from suspension cultures of Taxus chinensis cells.13PubMed Central. Comprehensive strategies for paclitaxel production: insights from plant cell culture, endophytic microorganisms, and synthetic biology Between semisynthesis and cell culture, today’s paclitaxel supply depends almost entirely on renewable sources.
Which Cancers Paclitaxel Treats
Paclitaxel is FDA-approved for ovarian, breast, lung cancer, and Kaposi’s sarcoma, and it is used off-label against a wide range of other tumors including gastric, endometrial, cervical, prostate, and head and neck cancers, plus several types of lymphoma and leukemia.4Europe PMC / Molecular Biology of the Cell. How Taxol/paclitaxel kills cancer cells Phase I and II trials have demonstrated activity in refractory ovarian and breast carcinoma, lung cancer, head and neck cancers, and lymphoma.14Mayo Clinic Proceedings. Paclitaxel (Taxol): A Novel Anticancer Chemotherapeutic Drug
In ovarian cancer, paclitaxel combined with a platinum drug has been the standard first-line treatment for decades. That combination showed better progression-free and overall survival compared with the older regimen it replaced.15PubMed. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers In metastatic breast cancer, paclitaxel given alone produces objective response rates generally between 20 and 35 percent, comparable to other leading chemotherapy options.15PubMed. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers Those numbers may sound modest, but in the context of advanced cancers that have already spread, meaningful tumor shrinkage in a quarter to a third of patients is considered a strong result, and paclitaxel has remained a backbone of treatment regimens for more than 25 years.16PubMed Central. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Side Effects, Especially Nerve Damage
Because paclitaxel targets microtubules, and nerve cells depend heavily on microtubules for their long-distance internal transport, the drug’s most characteristic side effect is peripheral neuropathy: numbness, tingling, or pain in the hands and feet. The risk increases with the cumulative dose a patient receives.17PubMed Central. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives Most patients see improvement within three to six months after stopping treatment, though severe cases are less likely to resolve completely.18PubMed Central. Chemotherapy-Induced Peripheral Neuropathy: Current Status and Progress
Some patients also experience an acute pain syndrome in the days right after infusion, with muscle and joint pain appearing within one to four days. Severe acute pain after infusion has been reported to predict the later development of chronic neuropathy.18PubMed Central. Chemotherapy-Induced Peripheral Neuropathy: Current Status and Progress A prospective study of breast cancer patients identified several risk factors that substantially increase the odds of developing neuropathy: age over 45, a history of high blood pressure, cumulative drug doses above a certain threshold, vitamin D deficiency, anemia before starting treatment, and longer infusion times, among others.19Frontiers in Oncology. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study This kind of risk profiling is increasingly used to help oncologists anticipate which patients need closer monitoring or dose adjustments.
Reformulating the Drug for Better Delivery
Paclitaxel is essentially insoluble in water, which created a serious practical problem from the start. The original formulation dissolved it in a solvent called Cremophor EL, which itself caused allergic reactions severe enough that patients needed premedication with steroids and antihistamines. This is one of the rare cases where the drug’s delivery vehicle caused nearly as much trouble as the drug.
The most successful workaround has been nanoparticle albumin-bound paclitaxel, marketed as Abraxane. Instead of a harsh solvent, the drug is wrapped in tiny particles of human albumin, a protein the body already uses to carry molecules through the bloodstream. Abraxane is a solvent-free formulation that showed lower rates of toxicity in a large randomized trial while maintaining at least the same anticancer effect as standard paclitaxel.20PubMed Central. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer It has been approved for metastatic breast cancer and non-small cell lung cancer.21PubMed Central. Paclitaxel Nano-Delivery Systems: A Comprehensive Review It also removes the need for steroid premedication, simplifying the treatment experience for patients considerably.
When Tumors Stop Responding
Like most chemotherapy drugs, paclitaxel eventually stops working in some patients as their tumors develop resistance. Researchers have investigated the usual suspects: the drug-pump proteins that eject chemotherapy from cancer cells, mutations in the tubulin proteins that paclitaxel binds to, and shifts in which versions of tubulin the cancer cells produce. In ovarian cancer patients, a direct comparison of these mechanisms found that overproduction of a specific tubulin variant, class III beta-tubulin, was the most prominent driver of resistance. Classic drug-pump proteins showed no significant change between sensitive and resistant patients, and tubulin gene mutations were absent in all cases examined.22Clinical Cancer Research. Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer Patients
This finding matters because it changes the conversation about how to overcome resistance. If the problem were mostly about drug-pump proteins, researchers could focus on blocking those pumps. Instead, the tubulin-shift mechanism suggests that next-generation taxanes need to be designed to bind effectively even when cancer cells change which tubulin isoforms they express. That goal has driven ongoing work to develop new taxane derivatives with improved potency against resistant tumors.23Expert Opinion on Drug Discovery. Strategies for the drug discovery and development of taxane anticancer therapeutics
Fungi That Produce Paclitaxel on Their Own
In 1993, researchers reported something unexpected: a fungus living inside the bark of Pacific yew trees could produce paclitaxel independently. The organism, named Taxomyces andreanae, was isolated from the inner bark of Taxus brevifolia and confirmed to make taxol and related compounds when grown in liquid culture. The identification was rigorous, involving mass spectrometry, chromatography, and monoclonal antibodies specific to paclitaxel.24PubMed. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew
The discovery raised the tantalizing possibility of producing paclitaxel by fermenting fungi rather than harvesting or culturing plant cells. In the decades since, endophytic fungi from yew species around the world, including the Himalayan yew (Taxus wallichiana), have been found to harbor paclitaxel-producing organisms. One study examining the beta-tubulin genes of these endophytes found signs of evolutionary selection at positions involved in paclitaxel binding, which hints that fungi may have evolved tubulin variants that tolerate their own taxol production.25Frontiers in Microbiology. Taxol and β-tubulins from endophytic fungi isolated from the Himalayan Yew, Taxus wallichiana Zucc. However, fungal yields of paclitaxel remain far too low for commercial production, and the organisms tend to lose their ability to make the drug after being cultured away from their host plant for extended periods. Why fungi produce paclitaxel in the first place, and whether the plant’s own biosynthetic pathway was somehow transferred to or shared with its microbial inhabitants, remains an open question in chemical ecology.
Mapping the Biosynthetic Pathway
Paclitaxel is one of the most structurally complex small molecules produced by any plant. Its biosynthesis involves roughly 19 enzymatic steps, and for decades many of those steps were unknown, which limited efforts to engineer its production in microorganisms or to boost yields in plant cell culture.
By the mid-2000s, researchers had characterized over half of the pathway enzymes and cloned their corresponding genes, covering both early and late segments of the biosynthetic route.26PubMed Central. Taxol biosynthesis and molecular genetics Genome sequencing of yew species has since revealed that the pathway relies on a series of enzymes including a key cyclase that builds the initial taxane skeleton, multiple enzymes that add oxygen atoms to different positions, and several that attach chemical side groups. The pathway also involves tandem gene duplications, where copies of the same gene diverged over evolutionary time to take on slightly different functions.27Molecular Plant. The Taxol Plant: From Pacific Yew to Cancer Treatment
A major breakthrough came from a 2025 study that used single-cell approaches to profile yew cells under many different conditions simultaneously. By observing which genes activated together across cell types and perturbations, the team identified eight previously unknown genes in the paclitaxel pathway and enabled the biosynthesis of a critical late-stage intermediate called baccatin III.28Nature. Discovery of FoTO1 and Taxol genes enables biosynthesis of baccatin III If the complete pathway can eventually be reconstructed in a fast-growing organism like yeast or bacteria, it could transform paclitaxel manufacturing by bypassing both plant cultivation and chemical semisynthesis entirely.
Who Owns a Drug From a Public Forest
The commercialization of paclitaxel also triggered one of the early public debates about who profits from biodiversity. The Pacific yew grew on public land, and the basic research identifying taxol’s anticancer properties was funded by the U.S. government through the NCI. Yet in 1991, Bristol-Myers Squibb was granted exclusive rights to supply paclitaxel from Pacific yew under a Cooperative Research and Development Agreement.29PubMed. Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug taxol The arrangement was meant to accelerate the drug’s development, but it provoked significant backlash. Critics argued that publicly funded discoveries from publicly owned forests were being handed to a private company, which would then charge patients and insurers for the final product. The controversy foreshadowed broader fights over biopiracy, natural-product drug pricing, and access to medicines derived from biodiversity that continue today.
The pricing issue has only grown more complex. As patent protections on the original formulation expired and generics became available, the cost of standard paclitaxel dropped. But newer formulations like Abraxane, protected by their own patents, carried premium prices. In oncology generally, reformulations and delivery innovations can extend the commercial life of a molecule far beyond its original patent window, a pattern paclitaxel exemplifies neatly.